Tiazofurin action in leukemia

Evidence for down-regulation of oncogenes and synergism with retinoic acid

George Weber, Yasufumi Yamaji, Masami Nagai, Yutaka Natsumeda, Hiremagalur N. Jayaram, Weining Zhen, Edith Paulik

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

New light was thrown on the action of tiazofurin in the treatment of end-stage leukemic patients and in leukemic cells in tissue culture. 1. 1. In a population of 21 consecutive patients 50% responded to tiazofurin treatment, confirming the usefulness of this therapy in end-stage leukemia. 2. 2. In leukemic patients treated with tiazofurin and allopurinol reciprocal action was manifested in the increase in hypoxanthine and the decrease in uric acid concentrations in the plasma. On discontinuation of allopurinol, hypoxanthine levels steeply declined but uric acid concentration increased slowly, taking days to reach pretreatment level. 3. 3. With a new and sensitive method the concentration of the active metabolite of tiazofurin, TAD, was measured in the mononuclear cells of tiazofurin-treated patients. Approximately 5 to 13% of the plasma tiazofurin level was observed as TAD in the mononuclear cells. This TAD concentration was sufficient to account for the inhibition of IMP DH in these cells. 4. 4. Tiazofurin or retinoic acid caused differentiation of HL-60 leukemic cells and inhibition of cell proliferation. 5. 5. By treating leukemic cells incubated with tiazofurin or retinoic acid also with guanosine it was elucidated that the mechanism of the two drugs differed since only the tiazofurin effects were counteracted by guanosine. 6. 6. Tiazofurin and retinoic acid together in HL-60 cells provided synergistic impact on differentiation and cytotoxicity. 7. 7. Tiazofurin resulted in down-regulation of the expression of ras and myc oncogenes in three systems: K562 human erythroleukemic cells, rat hepatoma 3924A cells and human HL-60 leukemia cells. 8. 8. Because both tiazofurin and retinoic acid are licensed drugs, their potential use in combination chemotherapy may have clinical relevance in the treatment of end-stage leukemia where our earlier studies have demonstrated the usefulness of tiazofurin.

Original languageEnglish
Pages (from-to)35-45
Number of pages11
JournalAdvances in Enzyme Regulation
Volume30
Issue numberC
DOIs
StatePublished - 1990

Fingerprint

tiazofurin
Tretinoin
Oncogenes
Leukemia
Down-Regulation
HL-60 Cells
Allopurinol
Hypoxanthine
Guanosine
Uric Acid
Plasmas

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Tiazofurin action in leukemia : Evidence for down-regulation of oncogenes and synergism with retinoic acid. / Weber, George; Yamaji, Yasufumi; Nagai, Masami; Natsumeda, Yutaka; Jayaram, Hiremagalur N.; Zhen, Weining; Paulik, Edith.

In: Advances in Enzyme Regulation, Vol. 30, No. C, 1990, p. 35-45.

Research output: Contribution to journalArticle

Weber, George ; Yamaji, Yasufumi ; Nagai, Masami ; Natsumeda, Yutaka ; Jayaram, Hiremagalur N. ; Zhen, Weining ; Paulik, Edith. / Tiazofurin action in leukemia : Evidence for down-regulation of oncogenes and synergism with retinoic acid. In: Advances in Enzyme Regulation. 1990 ; Vol. 30, No. C. pp. 35-45.
@article{aaa329b1b27442158cd36176ba632ac8,
title = "Tiazofurin action in leukemia: Evidence for down-regulation of oncogenes and synergism with retinoic acid",
abstract = "New light was thrown on the action of tiazofurin in the treatment of end-stage leukemic patients and in leukemic cells in tissue culture. 1. 1. In a population of 21 consecutive patients 50{\%} responded to tiazofurin treatment, confirming the usefulness of this therapy in end-stage leukemia. 2. 2. In leukemic patients treated with tiazofurin and allopurinol reciprocal action was manifested in the increase in hypoxanthine and the decrease in uric acid concentrations in the plasma. On discontinuation of allopurinol, hypoxanthine levels steeply declined but uric acid concentration increased slowly, taking days to reach pretreatment level. 3. 3. With a new and sensitive method the concentration of the active metabolite of tiazofurin, TAD, was measured in the mononuclear cells of tiazofurin-treated patients. Approximately 5 to 13{\%} of the plasma tiazofurin level was observed as TAD in the mononuclear cells. This TAD concentration was sufficient to account for the inhibition of IMP DH in these cells. 4. 4. Tiazofurin or retinoic acid caused differentiation of HL-60 leukemic cells and inhibition of cell proliferation. 5. 5. By treating leukemic cells incubated with tiazofurin or retinoic acid also with guanosine it was elucidated that the mechanism of the two drugs differed since only the tiazofurin effects were counteracted by guanosine. 6. 6. Tiazofurin and retinoic acid together in HL-60 cells provided synergistic impact on differentiation and cytotoxicity. 7. 7. Tiazofurin resulted in down-regulation of the expression of ras and myc oncogenes in three systems: K562 human erythroleukemic cells, rat hepatoma 3924A cells and human HL-60 leukemia cells. 8. 8. Because both tiazofurin and retinoic acid are licensed drugs, their potential use in combination chemotherapy may have clinical relevance in the treatment of end-stage leukemia where our earlier studies have demonstrated the usefulness of tiazofurin.",
author = "George Weber and Yasufumi Yamaji and Masami Nagai and Yutaka Natsumeda and Jayaram, {Hiremagalur N.} and Weining Zhen and Edith Paulik",
year = "1990",
doi = "10.1016/0065-2571(90)90007-O",
language = "English",
volume = "30",
pages = "35--45",
journal = "Advances in Biological Regulation",
issn = "2212-4926",
publisher = "Elsevier BV",
number = "C",

}

TY - JOUR

T1 - Tiazofurin action in leukemia

T2 - Evidence for down-regulation of oncogenes and synergism with retinoic acid

AU - Weber, George

AU - Yamaji, Yasufumi

AU - Nagai, Masami

AU - Natsumeda, Yutaka

AU - Jayaram, Hiremagalur N.

AU - Zhen, Weining

AU - Paulik, Edith

PY - 1990

Y1 - 1990

N2 - New light was thrown on the action of tiazofurin in the treatment of end-stage leukemic patients and in leukemic cells in tissue culture. 1. 1. In a population of 21 consecutive patients 50% responded to tiazofurin treatment, confirming the usefulness of this therapy in end-stage leukemia. 2. 2. In leukemic patients treated with tiazofurin and allopurinol reciprocal action was manifested in the increase in hypoxanthine and the decrease in uric acid concentrations in the plasma. On discontinuation of allopurinol, hypoxanthine levels steeply declined but uric acid concentration increased slowly, taking days to reach pretreatment level. 3. 3. With a new and sensitive method the concentration of the active metabolite of tiazofurin, TAD, was measured in the mononuclear cells of tiazofurin-treated patients. Approximately 5 to 13% of the plasma tiazofurin level was observed as TAD in the mononuclear cells. This TAD concentration was sufficient to account for the inhibition of IMP DH in these cells. 4. 4. Tiazofurin or retinoic acid caused differentiation of HL-60 leukemic cells and inhibition of cell proliferation. 5. 5. By treating leukemic cells incubated with tiazofurin or retinoic acid also with guanosine it was elucidated that the mechanism of the two drugs differed since only the tiazofurin effects were counteracted by guanosine. 6. 6. Tiazofurin and retinoic acid together in HL-60 cells provided synergistic impact on differentiation and cytotoxicity. 7. 7. Tiazofurin resulted in down-regulation of the expression of ras and myc oncogenes in three systems: K562 human erythroleukemic cells, rat hepatoma 3924A cells and human HL-60 leukemia cells. 8. 8. Because both tiazofurin and retinoic acid are licensed drugs, their potential use in combination chemotherapy may have clinical relevance in the treatment of end-stage leukemia where our earlier studies have demonstrated the usefulness of tiazofurin.

AB - New light was thrown on the action of tiazofurin in the treatment of end-stage leukemic patients and in leukemic cells in tissue culture. 1. 1. In a population of 21 consecutive patients 50% responded to tiazofurin treatment, confirming the usefulness of this therapy in end-stage leukemia. 2. 2. In leukemic patients treated with tiazofurin and allopurinol reciprocal action was manifested in the increase in hypoxanthine and the decrease in uric acid concentrations in the plasma. On discontinuation of allopurinol, hypoxanthine levels steeply declined but uric acid concentration increased slowly, taking days to reach pretreatment level. 3. 3. With a new and sensitive method the concentration of the active metabolite of tiazofurin, TAD, was measured in the mononuclear cells of tiazofurin-treated patients. Approximately 5 to 13% of the plasma tiazofurin level was observed as TAD in the mononuclear cells. This TAD concentration was sufficient to account for the inhibition of IMP DH in these cells. 4. 4. Tiazofurin or retinoic acid caused differentiation of HL-60 leukemic cells and inhibition of cell proliferation. 5. 5. By treating leukemic cells incubated with tiazofurin or retinoic acid also with guanosine it was elucidated that the mechanism of the two drugs differed since only the tiazofurin effects were counteracted by guanosine. 6. 6. Tiazofurin and retinoic acid together in HL-60 cells provided synergistic impact on differentiation and cytotoxicity. 7. 7. Tiazofurin resulted in down-regulation of the expression of ras and myc oncogenes in three systems: K562 human erythroleukemic cells, rat hepatoma 3924A cells and human HL-60 leukemia cells. 8. 8. Because both tiazofurin and retinoic acid are licensed drugs, their potential use in combination chemotherapy may have clinical relevance in the treatment of end-stage leukemia where our earlier studies have demonstrated the usefulness of tiazofurin.

UR - http://www.scopus.com/inward/record.url?scp=0025059268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025059268&partnerID=8YFLogxK

U2 - 10.1016/0065-2571(90)90007-O

DO - 10.1016/0065-2571(90)90007-O

M3 - Article

VL - 30

SP - 35

EP - 45

JO - Advances in Biological Regulation

JF - Advances in Biological Regulation

SN - 2212-4926

IS - C

ER -